50,310 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Cambiar Investors LLC

Cambiar Investors LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 50,310 shares of the biopharmaceutical company’s stock, valued at approximately $31,908,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in REGN. GAMMA Investing LLC lifted its holdings in Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after purchasing an additional 814,713 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock valued at $1,485,527,000 after purchasing an additional 810,144 shares in the last quarter. Nuveen LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $343,764,000. Pacer Advisors Inc. lifted its holdings in Regeneron Pharmaceuticals by 2,296.9% during the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock valued at $258,366,000 after purchasing an additional 390,374 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in Regeneron Pharmaceuticals by 171.0% during the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company’s stock valued at $305,311,000 after purchasing an additional 303,785 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 2.6%

NASDAQ REGN opened at $580.41 on Friday. The company’s 50-day moving average price is $544.21 and its 200-day moving average price is $594.90. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock has a market cap of $61.52 billion, a PE ratio of 14.63, a PEG ratio of 1.93 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The firm had revenue of $3,675,600 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the business posted $11.56 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.87%.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 target price on the stock. in a report on Friday, August 1st. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday. Robert W. Baird lowered their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a report on Friday, April 25th. Finally, BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $838.00.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.